---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-057115"
form_type: "8-K"
ticker: "VYGR"
cik: "0001640266"
company_name: "Voyager Therapeutics, Inc."
filed_at: "2026-05-07T23:59:59+00:00"
generated_at: "2026-05-14T21:49:34.495063+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Voyager Q1 net loss $27.9M, cash $172M into 2028; VY1706 tau gene therapy on track for H2 dosing

## Summary
- Net loss $27.9M (Q1 2026) vs $31.0M (Q1 2025); revenue $2.6M down from $6.5M due to lower collaboration revenue.
- Cash, equivalents and marketable securities $171.7M; runway expected into 2028.
- VY1706 tau silencing gene therapy: IND-enabling GLP tox completed; FDA IND on track for Q2, first-in-human dosing H2 2026.
- VY7523 anti-tau antibody: tau PET imaging efficacy data from MAD trial expected H2 2026.
- Neurocrine's NBIB-'223 for Friedreich's ataxia: GLP tox completed, FDA orphan drug designation; clinical trial H2 2026 pending IND.

## SEC filing metadata
- accession: 0001104659-26-057115
- form_type: 8-K
- ticker: VYGR
- cik: 0001640266
- company_name: Voyager Therapeutics, Inc.
- filed_at: 2026-05-07T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1640266/000110465926057115/0001104659-26-057115-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1640266/000110465926057115/vygr-20260507x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-057115
- JSON: https://secwatch.observer/filing/0001104659-26-057115.json
- Plain text: https://secwatch.observer/filing/0001104659-26-057115.txt

## Source-grounded claims
- claim_id: 5bc14f4247f2e3110a29ee7bf04224286c7812ef
  claim: Voyager Therapeutics, Inc. reported first quarter 2026 results: revenue $2.6 million, net income $27.9 million.
  evidence_excerpt: Collaboration revenue was $2.6 million for the three months ended March 31, 2026, compared to $6.5 million for the first quarter of 2025.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1640266/000110465926057115/0001104659-26-057115-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.